Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
31 results about "Cognitive regression" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Childhood onset SCA2 is rare and only the infantile onset form has been well-characterized clinically. This article describes a girl who met all developmental milestones until age 3 ½ years when she experienced cognitive regression that preceded motor regression by 6 months.
Compositions and methods for improving or preserving brain function
InactiveUS20070179197A1Improve performancePrevent and reduce delayBiocideNervous disorderRegimenExercise performance
The present invention is related to mammalian nutrition and effects thereof in individuals with age associated cognitive decline such as Age Associated Memory Inpairment (AAMI) or a dementing illness such as Alzheimer's disease or related dementia, or Mild Cognitive Impairment, such as improving performance in, or reversal, prevention, reducing and delaying decline in, one or more of cognitive function, memory, behavior, cerebrovascular function, motor function, and / or brain physiology are seen. In particular, the present invention utilizes medium chain triglycerides, in one embodiment, administered as part of a long-term treatment regimen, to preserve or improve learning, attention, motor performance, cerebrovascular function, social behavior, and to increase activity levels, particularly in aging mammals.
Owner:ACCERA INC
Novel compounds
This invention relates to compounds of formula Itheir use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and / or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, X, R1, R2, R3 have meanings given in the description.
Owner:BOEHRINGER INGELHEIM INT GMBH
Novel compounds
This invention relates to compounds of formula Itheir use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and / or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, Ar, R1, R2, R3 have meanings given in the description.
Owner:BOEHRINGER INGELHEIM INT GMBH
Novel compounds
This invention relates to compounds of formula Itheir use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and / or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, Ar, R1, R2, R3 have meanings given in the description.
Owner:BOEHRINGER INGELHEIM INT GMBH
Novel compounds
This invention relates to compounds of formula Itheir use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and / or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, X, R1, R2, R3 have meanings given in the description.
Owner:BOEHRINGER INGELHEIM INT GMBH
Compositions and methods for enhancing neurogenesis in animals
InactiveUS20160367509A1Increase neurogenesisHydrocarbon active ingredientsNervous disorderCognitively impairedAntioxidant
The invention provides methods for enhancing neurogenesis in an animal. In one embodiment, a method for enhancing neurogenesis in an animal can comprise identifying an animal that is suffering from cognitive decline, that is at risk of becoming cognitively impaired, that is diagnosed with a disease, disorder, or other condition that affects its cognitive abilities, or that is at risk of contracting a disease, disorder, or other condition that affects its cognitive abilities, and administering a composition comprising an unsaturated fatty acid (UFA), a nitric oxide releasing compound (NORC), a B vitamin, and an antioxidant, to the animal, wherein the composition is administered in an amount effective for enhancing neurogenesis in the animal.
Owner:SOC DES PROD NESTLE SA
Genetic and image biomarkets associated with decline in cognitive measures and brain glucose metabolism in populations with alzheimer's disease or those susceptible to developing alzheimer's disease
InactiveUS20160177390A1Faster decline in brain glucose metabolismFaster 36 month cognitive declineMicrobiological testing/measurementLibrary screeningGenes mutationAmyloid beta
The present disclosure is based on the identification of biomarkers of combined genetic variants and imaging measurements, in predicting faster decline in cognitive measures and brain glucose metabolism in populations with Alzheimer's disease or those susceptible to developing Alzheimer's disease. The present disclosure provides a method of treating a patient with Alzheimer's disease (AD) or a subject susceptible to developing AD, comprising: (a) assaying a sample obtained from an early-stage AD patient or a subject susceptible to developing AD for the presence of a brain-derived neurotrophic factor (BDNF) gene mutation and / or a protein tyrosine phosphatase receptor-type, Z polypeptide 1 (Ptprz1) gene mutation; (b) determining whether the patient or subject is positive for brain amyloid-beta (Aβ), wherein the presence of brain Aβ in combination with the BDNF gene and / or Ptprz1 gene mutation correlates with a prediction of rapid cognitive decline; and (c) treating the patient or subject with early and aggressive therapy appropriate to treat AD with rapid cognitive decline.
Owner:BIOGEN INT NEUROSCI
Substituted triazoles useful as mGlu5 receptor modulators
Owner:BOEHRINGER INGELHEIM INT GMBH
Method for early prediction of neurodegenerative decline
PendingUS20210228079A1Easy to useImage enhancementMedical imagingEarly predictionPredictive biomarker
The present invention relates to a method for predicting neurodegenerative decline and / or its severity for a patient, especially of cognitive impairment (CI). Strokes and Parkinson's disease are frequently associated with occurrence of long-term cognitive impairment or dementia with still incompletely resolved mechanisms. The discovery of diagnostic and predictive biomarkers thus remains a major challenge. The method of the invention uses radiomics corresponding to texture features extracted from a plurality of previously-acquired medical brain images and correlated with previously-acquired clinical and / or biological data. A classifier is trained beforehand for learning these radiomics, and then operated on radiomics computed from at least one brain image of a patient to generate a score representative of its risks of neurodegenerative decline. By applying this method on a cohort of 160 MCI and non-MCI patients, the inventors show that MCI patients could be early predicted with a mean accuracy of 88%. In the same way, the method was able to discriminate very early stages of cognitive decline in a Parkinson's disease population of 100 patients.
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +2
Compounds
Owner:BOEHRINGER INGELHEIM INT GMBH
Novel compounds
This invention relates to compounds of formula Itheir use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and / or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. R1, R2, R3, R4, Q have meanings given in the description.
Owner:BOEHRINGER INGELHEIM INT GMBH
System and method for detecting cognitive decline using speech analysis
System and method for detecting cognitive decline in a subject using a classification system for detecting cognitive decline in the subject based on a speech sample. The classification system is trained using speech data corresponding to audio recordings of speech from normal and cognitive decline patients to generate an ensemble classifier comprising a plurality of component classifiers and an ensemble module. Each of the plurality of component classifiers is a machine-learning classifier configured to generate a component output identifying a sample data as corresponding to a normal patient or a cognitive patient. The machine-learning classifier is generated based on a subset of available features. The ensemble module receives component outputs from all of the component classifiers and generates an ensemble output identifying the sample data as corresponding to a normal or cognitive decline patient based on the component outputs.
Owner:JANSSEN PHARMA NV
Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
Compositions comprising cyclobenzaprine, and methods for the treatment or prevention of agitation, psychosis and / or cognitive decline and associated symptoms thereof in dementia and other neurodegenerative conditions.
Owner:TONIX PHARMA HLDG LTD
Medical food for cognitive decline
ActiveUS9254280B2Improve cognitive functionSlowing or treating cognitive declineOrganic active ingredientsNervous disorderDiseaseFisetin
Nutraceutical formulations that improve cognitive function in adults diagnosed with neurodegenerative disease are provided, which comprise a combination of fisetin and DHA.
Owner:SALK INST FOR BIOLOGICAL STUDIES +2
Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
Owner:BOEHRINGER INGELHEIM INT GMBH
Methods and systems for identification and treatment of pathological neurodegeneration and age-related cognitive decline
PendingUS20200400688A1Lower Level RequirementsReduce severityOrganic active ingredientsNervous disorderDepressantT cell
Methods and systems for diagnosing, providing prophylaxis, and treating one or more age-related neurodegeneration or pathological cognitive impairment are provided. An increased presence of CD103+ resident memory CD8+ T cells (CD8+ TRM) can be detected in blood sample obtained from the human subjects with one or more symptoms of loss of short-term or long-term memory, decreased ability to maintain focus, and decreased problem-solving capacity. An increased presence of CD103+ CD8+ TRM can be compared to a value obtained from one or a pool of healthy human subjects with none of the one or more symptoms. One or more of a therapeutically effective amount of: an inhibitor of cluster of differentiation (CD103), an inhibitor of perforin-1, and an inhibitor of interferon gamma (IFNγ) can be administered as treatment of age-related neurodegeneration or pathological cognitive impairment. Pathological neurodegeneration can include Parkinson's disease, multiple sclerosis, or Alzheimer' s disease.
Owner:CEDARS SINAI MEDICAL CENT
Methods for Improving Cognitive Function and Decreasing Heart Rate
The present invention is directed to methods of improving cognitive function in subjects having age related cognitive decline or mild cognitive impairment and to methods of decreasing heart rate in a subject by administering dosage forms comprising docosahexaenoic acid (DHA) substantially free of eicosapentaenoic acid (EPA).
Owner:DSM IP ASSETS BV
Methods for identifying pre-disposition to cognitive decline and agents for reducing or preventing cognitive decline, or improving cognitive ability
PendingUS20210263048A1Accelerated cognitive declineReduce riskNervous disorderDisease diagnosisMetabolitePsychiatry
A method for identifying pre-disposition to cognitive decline in a subject, the method comprising determining levels of: (a) omega-3 fatty acids, and vitamin D or a metabolite thereof; (b) omega-3 fatty acids, and homocysteine; (c) vitamin D or a metabolite thereof, and homocysteine; or (d) omega-3 fatty acids, vitamin D or a metabolite thereof, and homocysteine, independently in one or more samples obtained from the subject.
Owner:SOC DES PROD NESTLE SA
N-aryl-piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
Owner:BOEHRINGER INGELHEIM INT GMBH
Structured molecular vectors for Anti-inflammatory compounds and uses thereof
PendingUS20220162239A1Good anti-inflammatory activityReduce frequencyOrganic active ingredientsNervous disorderInjury brainNeuro-degenerative disease
The present invention relates to structured molecular vectors of formula (I), compounds of formula (II) and pharmaceutical compositions comprising such compounds. The invention also relates to such pharmaceutical compositions for use for preventing and / or treating a disease chosen among an inflammatory disease or a disease associated with a cognitive disorder. The invention further relates to such pharmaceutical compositions for use for preventing cognitive decline or restoring cognitive functions altered in brain injuries and / or in traumatic brain injuries and / or in a neuroinflammatory disease, and / or in a neurodegenerative disease.
Owner:UNIV CLAUDE BERNARD LYON 1 +3
Compounds
Owner:BOEHRINGER INGELHEIM INT GMBH
System and method for detecting cognitive decline using speech analysis
Owner:JANSSEN PHARMA NV
Methods and systems for detecting indications of cognitive decline
PendingUS20220167893A1Shorten the progressMental therapiesSensorsPhysical medicine and rehabilitationPhysical therapy
Systems and methods for detecting and managing cognitive decline of a person using a cognitive training device are provided involving a first information source having a device including a sensor configured to detect sensor data corresponding to a first behavior of the person, wherein the first behavior represents a first deviation from a first expected pattern; a second information source configured to receive, store, and transmit data corresponding to a second behavior of the person, wherein the data indicates the second behavior represents a second deviation from a second expected pattern; and a processor configured to analyze the sensor data and the data to determine whether a predetermined threshold has been reached indicating the person is experiencing a first stage of cognitive decline, and generate actionable information to assist a user in determining a treatment for the person to delay the progression of the first stage of cognitive decline.
Owner:KONINKLJIJKE PHILIPS NV
Pulsative gnrh administration for treating cognitive disorders
PendingUS20220202895A1Induces cognitive and olfactory impairmentsOrganic active ingredientsNervous disorderOlfactory disorderCognitive diseases
The present invention pertains to novel therapeutic ways for treating cognitive disorders associated with olfactory dysfunction. By using a mouse model of Down syndrome (DS—Ts65Dn mice), the present inventors have demonstrated that GnRH insufficiency is involved in the age-dependent acquisition of cognitive decline in DS and that pulsatile GnRH treatment allows reversing olfactory- and cognitive-associated impairments in DS. The present inventors have further demonstrated that GnRH insufficiency is involved in the pathological pathways of cognitive disorders in which the cognitive decline is associated with olfactory dysfunction, and, accordingly, that pulsatile GnRH administration can be used for the treatment of cognitive disorders associated with olfactory dysfunction. Accordingly, the present invention pertains to the use of GnRH for the treatment of cognitive disorders, said GnRH being administered by pulsatile administration. The present invention further pertains to a miR-200 and / or a miR-155, which are known to be involved in GnRH-secretion regulation, for use in the treatment of cognitive disorders.
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +2
Methods and compositions for treating decreased cognitive ability
Disclosed are methods and compositions for treating cognitive decline in subjects in need. More specifically, disclosed are methods of administrating exogenous adropin to subjects suffering from, or at risk of, cognitive decline. Also disclosed are subjects who would benefit from such treatment and pharmaceutical acceptable compositions comprising adropin, adropin34-76, and derivatives or variations thereof.
Owner:SAINT LOUIS UNIVERSITY +1
Systems and methods for detecting cognitive decline with mobile devices
PendingCN114096195AEvaluation of blood vesselsSensorsPhysical medicine and rehabilitationComputer science
Embodiments of the present disclosure relate to systems and methods for detecting cognitive decline of a subject by using the passively obtained data from at least one mobile device. In an exemplary embodiment, a computer-implemented method comprises receiving the passively obtained data from at least one mobile device. The method further comprises generating the digital biomarker data from the passively obtained data. The method further comprises analyzing the digital biomarker data to determine whether the subject is exhibiting signs of cognitive decline.
Owner:ELI LILLY & CO
Compositions and methods for the treatment and prevention of cognitive decline and preservation of neuronal function
ActiveUS11278519B2Reducing treatmentPreserving and improving and increasing neuronal functionOrganic active ingredientsNervous disorderPerylene derivativesNeuron
Owner:SENESCENCE LIFE SCI PTE LTD
Method for generating cognitive decline detection tool, method for measuring cognitive decline and tool for measuring same
ActiveUS11395621B2Medical simulationMedical automated diagnosisPhysical medicine and rehabilitationClinical psychology
Owner:TOUBIB MEDIA INC
Omega-3 fatty acid and vitamin d levels to identify and attenuate cognitive aging in individuals
Owner:SOC DES PROD NESTLE SA
Compositions and methods for the treatment and prevention of cognitive decline and preservation of neuronal function
ActiveUS20200170995A1Reducing treatmentPreserving and improving and increasing neuronal functionOrganic active ingredientsNervous disorderPerylene derivativesNeuron
Described herein are compositions and methods for the treatment and prevention of cognitive decline in subjects. Generally, among other potential components, the compositions comprise Centella asiatica or an extract thereof; α-tocopherol or a derivative thereof; ginseng or an extract thereof; a selenium compound, and α-lipoic acid. Also provided are methods of making such compositions.
Owner:SENESCENCE LIFE SCI PTE LTD
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com